An Open Label Phase II Study of Oral Treatment With Sunitinib (Sutent) in Patients Suffering From Hormone Refractory Prostate Cancer After Progression With Docetaxel Based Regimen.
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2013
At a glance
- Drugs Sunitinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms PROSUT
- 17 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Jul 2012 Last checked against European Clinical Trials Database record.
- 24 Sep 2008 New trial record.